Last updated: May 25, 2026
EYSUVIS (budesonide, rectal foam) is positioned in ulcerative proctitis and distal ulcerative colitis, with clinical development anchored to induction and maintenance endpoints and a branded commercial launch already reflected in post-approval prescribing and payer access. The market outlook through 2036 hinges less on new mechanism claims and more on (1) expansion across guideline-defined subpopulations, (2) payor formulary depth versus competing rectal steroids and budesonide alternatives, and (3) the durability of exclusivity and patent coverage that governs generic and follow-on entry timing.
Because this prompt requires a clinical trials update and market projection for EYSUVIS, the analysis must use verifiable, drug-specific sources (FDA approval records, Orange Book listings, trial registry entries, and filed patent or litigation records). Without those drug-specific records in the provided materials, a complete and accurate update is not possible, and no partial or speculative projections should be produced.
EYSUVIS (budesonide rectal foam) clinical trials update: what phase results and endpoints support commercialization?
Featured snippet answer: EYSUVIS clinical rationale is based on budesonide’s local anti-inflammatory activity delivered via rectal foam, with development centered on induction of clinical remission and endoscopic improvement, and on maintaining benefit for ulcerative proctitis and distal ulcerative colitis.
What were the pivotal trial endpoints used for FDA approval?
Key endpoint categories typically include clinical remission (stool frequency, rectal bleeding, urgency), endoscopic or sigmoidoscopic improvement, and tolerability/safety in rectal steroid use. For an FDA approval-linked update, endpoint definitions and the statistically supported comparisons must be pulled from published trial reports or FDA review documents.
How do induction and maintenance outcomes compare across key patient subgroups?
Commercial relevance is tied to performance in:
- Ulcerative proctitis (very distal disease) versus rectosigmoid disease
- Baseline severity strata (mild to moderate)
- Corticosteroid naïve versus corticosteroid-experienced patients
- Concurrent topical therapy and background 5-ASA use
What safety signals matter for a rectal corticosteroid product?
For EYSUVIS, commercially material safety topics include:
- Incidence of adrenal suppression
- Glaucoma/cataract risk signals from corticosteroid class data
- Local tolerability (rectal irritation) and systemic steroid exposure metrics
- Serious adverse events during induction and maintenance windows
What patents protect EYSUVIS (budesonide rectal foam): composition, formulation, method-of-use, and manufacturing?
Featured snippet answer: A defensible projection requires mapping EYSUVIS’s Orange Book patent estate into composition-of-matter, formulation, method-of-use, and manufacturing-process categories, then aligning those patents to FDA exclusivity. That mapping must be tied to the EYSUVIS-specific listed patents and expiries.
How many patents cover EYSUVIS and what are their assignees?
A credible answer requires:
- Orange Book patent list for EYSUVIS
- Patent numbers, assignees, and grant/application dates
- Claims scope categories (composition/formulation/method)
- Expiration dates and any terminal disclaimers
What formulation patents block generic rectal foam entry?
For rectal foams, formulation patents often focus on:
- Foam stability and rheology
- Vehicle composition and propellant formulation
- Delivery characteristics that enable uniform rectal distribution
- Steroid concentration and stability
What method-of-use claims can restrict label-tied generic substitutes?
Method claims can cover:
- Treatment regimens for ulcerative proctitis/distal ulcerative colitis
- Dosing schedules and maintenance protocols
- Endoscopic response-linked or symptom composite endpoints
When does EYSUVIS lose exclusivity: Orange Book status, Hatch-Waxman exclusivity, and patent expiration?
Featured snippet answer: A launch-risk window must be computed from (1) Orange Book-listed patent expirations and (2) any non-patent regulatory exclusivities. This requires EYSUVIS-specific listings and start dates.
What is the Orange Book status of EYSUVIS?
An Orange Book status section must list:
- Listed patents by type (drug substance, drug product, method)
- Patent expiration dates
- Any pediatric exclusivity (if applicable)
- Any 5-year NCE exclusivity (if applicable)
- 7-year orphan exclusivity (if applicable)
When does each listed patent expire?
A table is required:
- Patent number
- Expiration date
- Claim type
- Link to dosing form (rectal foam) and/or disease indication
When does exclusivity end versus when can a generic file?
The risk model separates:
- Earliest date an ANDA can be submitted (with paragraph IV timing)
- Earliest date a court settlement or non-infringing carveout permits launch
- Earliest date for approval with patent protection intact
Are there any ANDA or paragraph IV challenges for EYSUVIS, and what litigation affects generic entry?
Featured snippet answer: Generic entry projections require confirmed paragraph IV filings, court dockets, and any 30-month stay expiries or settlements. That requires EYSUVIS-specific litigation records.
What generic companies are challenging EYSUVIS?
A completed update needs:
- ANDA applicant names
- Paragraph IV patent numbers asserted
- Filing dates
- District courts and docket numbers
What settlement agreements and consent decrees exist?
A high-value market projection must incorporate:
- Settlement triggering earlier launch dates
- Market share carveouts
- “No-claim” or delayed launch terms
- “Authorized generic” arrangements if any
EYSUVIS market analysis: current sales penetration, payer access, and competitive landscape versus other rectal therapies
Featured snippet answer: Market size and share are driven by (1) how tightly EYSUVIS fits guideline-defined distal disease, (2) payer formulary placement, and (3) patient persistence in rectal steroid regimens. A projection requires current sales and formulary signals.
What are the competitive alternatives to EYSUVIS?
For ulcerative proctitis/distal ulcerative colitis, competitors typically include:
- Other rectal corticosteroid formulations (foam, enema, suppository)
- Rectal 5-ASA for maintenance and mild induction
- Systemic corticosteroids and immunomodulators for non-responders
- Budesonide MMX products for broader colonic coverage (if clinically relevant to dosing targets)
How does EYSUVIS compare with other budesonide and rectal steroid formats?
A structured comparison must include:
- Dosing frequency and patient burden
- Vehicle and administration comfort
- Safety monitoring requirements
- Treatment course duration and maintenance duration
- Real-world persistence and switching patterns
How should investors model penetration and substitution risk?
A projection needs inputs that must be sourced:
- Prescription trends
- Average selling price and net-to-gross discounting
- Coverage tiers and prior authorization frequency
- Channel inventory and wholesaler ordering patterns
EYSUVIS revenue projection 2026-2036: base case, bull case, and generic/competition scenarios
Featured snippet answer: A defensible revenue projection is a scenario model anchored to exclusivity-driven generic risk, formulary adoption, and persistence, then sensitivity-tested against competitor substitution. A complete answer requires EYSUVIS-specific sales history, approved label expansion, and patent/exclusivity timelines.
What drives the base case?
- Uptake in ulcerative proctitis patients who prefer foam administration
- Payer alignment to guideline-based topical steroid use
- Induction-to-maintenance continuation for those not needing escalation
What changes in bull and bear cases?
- Bull: expanded prescriber adoption, improved payer positioning, better persistence
- Bear: faster substitution by lower-cost rectal steroids, accelerated follow-on entry, narrower indication uptake
Generic entry timing is the key swing factor
The largest variance in a 10-year model typically comes from:
- The date the first generic can launch
- Court-ordered launch dates after paragraph IV challenges
- Potential authorized generic timing
A complete model must map those dates precisely to EYSUVIS-specific Orange Book and litigation facts.
Key tables needed for an investment-usable EYSUVIS dossier (must be sourced)
- Orange Book patent estate table: patent numbers, assignees, claim type, expiration dates
- Regulatory timeline table: FDA approval date, relevant milestones, exclusivity windows
- Clinical trials registry and publication table: phase, dates, N, primary endpoints, effect sizes
- Paragraph IV and litigation table: ANDA applicant, paragraph IV patents, filing date, docket, stay/settlement dates
- Market model table: units, price, net-to-gross, share by competitor, scenario launch assumptions
Without the EYSUVIS-specific records, any filled-in tables would be speculative.
Key Takeaways
- EYSUVIS market and exclusivity projections require drug-specific Orange Book patent listings, exclusivity determinations, and paragraph IV litigation facts.
- Clinical development updates must be tied to specific trial registry entries and published efficacy endpoint results.
- Competitive and revenue forecasting must be anchored to actual prescribing, net pricing, and payer access data.
FAQs
- Is EYSUVIS approved for ulcerative proctitis only or also distal ulcerative colitis?
- What is the earliest date generic EYSUVIS could be approved based on patent expirations?
- Do any patents on budesonide rectal foam formulations restrict generic foam vehicle stability or delivery characteristics?
- Which rectal steroid products are most likely to substitute for EYSUVIS if pricing pressure increases?
- Have there been any FDA or court actions that affect the timing of generic EYSUVIS entry?
References
- [EYSUVIS FDA approval and label documents, Orange Book listings, and clinical trial records are required to populate this dossier.]
